The impact of EGFR inhibition on drug transport function in HNSCC is an additive effect to CTX activity which leads to multiple physiological changes, notably cell cycle arrest, inhibition of proliferation, and apoptosis, which alone promotes a substantial remission of HNSCC [18]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.